Serum Proteomics Analysis for Sepsis

Serum Proteomics Analysis for Dynamic Changes of Differential Proteins in Sepsis Patient With iTRAQ Labeling and LC-MS/MS

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01493466

Enrollment

100

Registered

2011-12-16

Start date

2010-05-31

Completion date

2012-03-31

Last updated

2011-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Death, Sepsis, Severe Sepsis, SIRS

Keywords

proteomics,, serum,, sepsis,, potential biomarkers,, dynamic changes, normal

Brief summary

Serum proteomics is a very useful tool to identify various disease. The purpose of the present study was to find differential proteins among patient with normal, SIRS, sepsis, severe sepsis, death and to screen potential biomarkers for their dynamic changes. Serum proteins were identified by iTRAQ labeling and LC-MS/MS. The bioinformatics analysis was performed with the Mascot software and the International Protein Index (IPI) and the Gene Ontology (GO) Database and KEGG pathway Database. The differentially expressed proteins were verified by Western blot by another sample collected from clinical.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Male and female aged 18 years old and over; * clinically confirmed infection; * fulfilled at least two criteria of systemic inflammatory response syndrome * (a) core temperature higher than 38 °C or lower than 36 °C * (b)respiratory rate above 20/min, or PCO2 below 32 mmHg * (c) pulse rate above 90/min, and * (d) white blood cell count greater than 12,000/μl or lower than \< 4,000/μl or less than 10% of bands.

Exclusion criteria

* younger than 18 years of age; * acquired immunodeficiency syndrome; * reduced polymorphonuclear granulocyte counts (\< 500 μL-1); * died within 24h after admission into the ICU, or refused to participate in the study, or declined treatment during the period of observation.

Design outcomes

Primary

Measure	Time frame	Description
Survival status	28 days after admission to ICU	The survival time of patients more than 28days is defined as survival. The survival time of patients less than 28days is defined as death.

Countries

China

Contacts

Primary ContactLongxiang Su, MD

slx77@163.com+86 15620952878

Outcome results